Funding, M&A, exec moves and hiring — every signal, the moment it breaks.See plans →
Verrica Pharmaceuticals closes a credit facility of up to $27.5 million for non-dilutive growth capital to support YCANTH® commercialization and a global Phase 3 program.
PUBLIC · VRCAAug 06, 2026•1 day ago
Amount Raised
$27.5 Million
Round Type
Debt Financing
West ChesterBiotechnologyHealthcareHealth CareTherapeutics
Investors
Paul B. Manning
Description
Verrica Pharmaceuticals has announced the closing of a credit facility for up to $27.5 million with an entity controlled by its largest shareholder, Paul B. Manning. This facility will support the commercialization of YCANTH® and the global Phase 3 program studying YCANTH for common warts treatment. It provides non-dilutive capital with no scheduled payments until maturity in December 2030
Company Information
Company
Verrica
Location
West Chester, Pennsylvania, United States
About
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. We believe there’s a better way to safely and effectively bring relief to patients, deliver peace of mind to parents and caregivers, and advance accessible therapies to prescribers and payers. We are focused on changing the narrative around skin diseases and making treatment a more efficient process for both physicians and patients.
Related People
Suggested for you
5 contacts
Verified contactsJeff, Regional Sales Director, West hidden hidden
West ChesterBiotechnologyHealthcareHealth CareTherapeutics